Theraclion Financial Statements From 2010 to 2025
| TCLIF Stock | USD 0.0002 0.00 0.00% |
Check Theraclion financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Theraclion's main balance sheet or income statement drivers, such as , as well as many indicators such as . Theraclion financial statements analysis is a perfect complement when working with Theraclion Valuation or Volatility modules.
Theraclion |
Theraclion SA Company Return On Asset Analysis
Theraclion's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Theraclion Return On Asset | -0.25 |
Most of Theraclion's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Theraclion SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Theraclion SA has a Return On Asset of -0.2533. This is 97.11% lower than that of the Healthcare sector and 98.6% lower than that of the Medical Devices industry. The return on asset for all United States stocks is 80.93% higher than that of the company.
Theraclion SA Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Theraclion's current stock value. Our valuation model uses many indicators to compare Theraclion value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Theraclion competition to find correlations between indicators driving Theraclion's intrinsic value. More Info.Theraclion SA is rated fifth in return on asset category among its peers. It is currently regarded as top stock in operating margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Theraclion's earnings, one of the primary drivers of an investment's value.About Theraclion Financial Statements
Theraclion stakeholders use historical fundamental indicators, such as Theraclion's revenue or net income, to determine how well the company is positioned to perform in the future. Although Theraclion investors may analyze each financial statement separately, they are all interrelated. For example, changes in Theraclion's assets and liabilities are reflected in the revenues and expenses on Theraclion's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Theraclion SA. Please read more on our technical analysis and fundamental analysis pages.
Theraclion SA develops echotherapy solutions using high intensity focused ultrasound system. The company was incorporated in 2004 and is based in Malakoff, France. Theraclion operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 24 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Theraclion Pink Sheet
Theraclion financial ratios help investors to determine whether Theraclion Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Theraclion with respect to the benefits of owning Theraclion security.